Astellas Pharma Inc., Innovation Lab
Makoto Omiya, PhD, is Head of the Core Discovery Unit at Astellas Pharma Inc. He specializes in CNS drug discovery and emphasizes translational science as essential for developing breakthrough therapeutics. Dr. Omiya has contributed to pioneering programs, including the world’s first patent for a dopamine D1 positive allosteric modulator, and advancing multiple small molecules into clinical development. Currently, he leads biomarker-driven projects to tackle the challenge of evaluating drug efficacy in CNS disorders, with a particular focus on circadian rhythm biology to advance innovative therapeutics.
Makoto Omiya, PhD, is Head of the Core Discovery Unit at Astellas Pharma Inc. He specializes in CNS drug discovery and emphasizes translational science as essential for developing breakthrough therapeutics. Dr. Omiya has contributed to pioneering programs, including the world’s first patent for a dopamine D1 positive allosteric modulator, and advancing multiple small molecules into clinical development. Currently, he leads biomarker-driven projects to tackle the challenge of evaluating drug efficacy in CNS disorders, with a particular focus on circadian rhythm biology to advance innovative therapeutics.